Morgan Stanley raised the target price of Moderna (MRNA.US) from $39 to $89.

Bitget

News

智通财经2026/08/20 08:01

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Morgan Stanley: Raised the target price of Moderna (MRNA.US) from $39 to $89.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Jefferies Group analyst Andrew Tsai stated that Moderna’s breakthrough in skin cancer vaccines positions the pharmaceutical company to have more than seven products on the market by 2027-28. The analyst noted that the company is diversifying its product portfolio to cover respiratory diseases, cancer treatments, and AI-designed drugs. The company’s 2026 revenue may increase by up to 10% from $1.9 billion in 2025, positioning it for potential break-even by 2028. The success of clinical trials fo

智通财经•2026/08/20 09:41